METHODS OF PREDICTING POST-TRANSFUSION SURVIVAL OF RED BLOOD CELLS

• US 20200132700A1
• Filed: 05/04/2017
• Published: 04/30/2020
• Est. Priority Date: 05/05/2016
• Status: Active Application

• Current Assignee: Bloodworks
• Original Assignee: Bloodworks
• Inventors: Zimring, James Charles, Fu, Xiaoyun
• Application Number:
  US16/099,090
• Publication Number:
  US 20200132700A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 35/18 Erythrocytes haemoglobin A61K38/42
• CPC Class Codes: A61M 1/0272 Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
• CPC Class Codes: G01N 2405/04 Phospholipids, i.e. phosphoglycerides
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 33/80 involving blood groups or blood types or red blood cells white blood cells G01N33/56972
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743

Abstract

Methods for predicting post-transfusion survival of red blood cells are provided herein. In some versions, the methods include measuring a level of lysophospholipids in a unit of red blood cells and predicting the post-transfusion survival of the red blood cells in the unit based on the measured level of lysophospholipids.

Claims

1. A method of predicting post-transfusion survival of red blood cells, the method comprising:

a) measuring a level of lysophospholipids in a unit of red blood cells; and

b) predicting the post-transfusion survival of the red blood cells in the unit based on the measured level of lysophospholipids.

2. The method of claim 1, wherein the lysophospholipids comprise Lysophosphatidylcholine, LysophosphatidylEthanolamine, or LysophosphatidylSerine.

3. The method of claim 2, wherein the lysophospholipids comprise Lysophosphatidylcholine.

4. The method of claim 2, wherein the lysophospholipids comprise LysophosphatidylEthanolamine.

5. The method of claim 2, wherein the lysophospholipids comprise LysophosphatidylSerine.

6. The method of claim 1, wherein method further comprises storing the unit of red blood cells for a length of time.

7. The method of claim 1, wherein the length of time is 30 days or more.

8. The method of claim 1, wherein method further comprises transfusing at least a portion of the unit of red blood cells to a subject.

9. A method of transfusing an amount of red blood cells to a subject, the method comprising:

a) collecting a unit of red blood cells from a human donor;

b) measuring a level of lysophospholipids in the unit of red blood cells;

c) predicting the post-transfusion survival of the red blood cells in the unit based on the measured level of lysophospholipids;

d) storing the unit of red blood cells for a length of time; and

e) transfusing an amount of the unit of red blood cells to a subject.

10. The method of claim 9, wherein the amount of the unit of red blood cells transfused is based on the predicted post-transfusion survival of the red blood cells.

11. The method of claim 9, wherein the amount of the unit of red blood cells transfused is low when the predicted post-transfusion survival is high.

12. The method of claim 9, wherein the length of time is 30 days or more.

13. The method of claim 9, wherein the lysophospholipids comprise Lysophosphatidylcholine, LysophosphatidylEthanolamine, or LysophosphatidylSerine.

18. The method according to claim 13, further comprising determining a higher level of the one or more markers in the stored blood sample compared to the control blood sample that indicates a lower RBC storage quality of the RBCs of the stored blood sample as compared to RBCs of the control blood sample and thereby predicting a lower post-transfusion survival of the of the RBCs of the stored blood sample than RBCs of the control blood sample, or determining an absence of a higher level of the one or more markers in the stored blood sample compared to the control blood sample.

19. The method according to claim 13, further comprising excluding the stored blood sample from use in the blood transfusion when a lower RBC storage quality of the RBCs of the stored blood sample is indicated as compared to the RBCs of the control blood sample, and using the stored blood sample in the blood transfusion when an absence of a higher level of the one or more markers in the stored blood sample compared to the control blood sample is determined.

14-16. -16. (canceled)

17. A method for determining the suitability of a stored blood sample comprising red blood cells (RBCs) for use in a blood transfusion, the method comprising the steps of:

a) measuring a level of one or more markers in the stored blood sample, wherein the one or more markers comprise lysophospholipids; and

b) comparing the level of the one or more markers in the stored blood sample with a level of the one or more markers present in a control blood sample determined to be suitable for use in a blood transfusion.

20. The method according to claim 17, wherein the amount of the unit of red blood cells transfused is based on the predicted post-transfusion survival of the red blood cells.

21. The method according to claim 17, wherein the amount of the unit of red blood cells transfused is low when the predicted post-transfusion survival is high.

22. The method according to claim 17, further comprising storing the sample for 30 days or more.

23. The method according to claim 17, wherein the lysophospholipids comprise Lysophosphatidylcholine, LysophosphatidylEthanolamine, or LysophosphatidylSerine.

24-26. -26. (canceled)